Compare FEAM & XGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FEAM | XGN |
|---|---|---|
| Founded | 2016 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Medical Specialities |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 89.1M | 253.9M |
| IPO Year | N/A | 2019 |
| Metric | FEAM | XGN |
|---|---|---|
| Price | $3.90 | $7.20 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 6 |
| Target Price | $8.13 | ★ $13.67 |
| AVG Volume (30 Days) | 74.8K | ★ 312.4K |
| Earning Date | 11-13-2025 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $63,599,000.00 |
| Revenue This Year | N/A | $22.15 |
| Revenue Next Year | $500.00 | $15.26 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 14.08 |
| 52 Week Low | $2.82 | $2.67 |
| 52 Week High | $24.84 | $12.23 |
| Indicator | FEAM | XGN |
|---|---|---|
| Relative Strength Index (RSI) | 44.83 | 31.11 |
| Support Level | $3.89 | $7.01 |
| Resistance Level | $4.21 | $7.33 |
| Average True Range (ATR) | 0.29 | 0.32 |
| MACD | 0.04 | 0.07 |
| Stochastic Oscillator | 60.53 | 27.14 |
5E Advanced Materials Inc is an exploration stage company focused on becoming a vertically integrated supplier of specialty boron and boron derivative materials whose mission is to enable decarbonization, increase food security, and ensure domestic supply of critical materials. It has a project located in southern California underpinned by a mineral resource that includes boron and lithium, with the boron being contained in a conventional boron mineral known as colemanite. The company seeks to extract and process the minerals into boric acid, boron materials, lithium carbonate, and potentially other co-products on a commercial scale.
Exagen Inc is a commercial-stage diagnostics company committed to addressing the unmet need for the accurate diagnosis and monitoring of patients affected by autoimmune rheumatic diseases. It currently markets ten testing products under its Avise brand to provide an accurate, timely, and differential diagnosis and to optimize the treatment of ARDs. It markets and sells solutions to community rheumatologists.